FluoroType® SARS-CoV-2 varID Q  

Identification of relevant SARS-CoV-2 mutations and viral load assessment

Destaques

SARS-CoV-2 variant detection

COVID-19 (Coronavirus disease 2019) has affected countries worldwide and rapid detection of individuals infected with SARS-CoV-2 has been an essential part of outbreak management to help mitigate pressures on healthcare services. SARS-CoV-2 variants are now of major public concern.
These novel lineages may show increased transmissibility and even bear the risk of immune evasion, therefore posing additional global threats in the attempt to control the viral spread as well as threatening the success of vaccination strategies. Identifying these variants helps to track their spread and enables epidemiological surveillance.

Identify SARS-CoV-2 mutations and assess viral load

FluoroType® SARS-CoV-2 varID Q is a multiplex PCR test for the detection and quantification of SARS-CoV-2. The assay allows simultaneous identification of different mutations in the S gene of SARS-CoV-2 by targeting four independent sequences within the SARS-CoV-2 genome. This multi-target approach provides confident identification of SARS-CoV-2 as well as differentiation between SARS-CoV-2 variants according to their underlying mutations. The different S gene mutations of SARS-CoV-2 are differentiated via melting curve analysis: N501Y, A67V + del69-70, del69-70, D80A and E484K.

 

The test is validated for use with nasopharyngeal and oropharyngeal swabs and contains reagents for up to 96 reactions. PCR results are produced in under two hours. Internal Controls monitor extraction, reverse-transcription and amplification for maximum confidence. The viral load assessment according to the NIBSC First WHO International Standard for SARS-CoV-2 RNA (in IU/ml) helps to monitor disease progression.

Results at a glance in combination with FluoroCycler® XT

The wizard-based FluoroSoftware® XT-IVD of the FluoroCycler® XT comfortably guides users through setup and result evaluation. Automatically generated reports enable fast, confident reporting without the need for individual interpretation.

In combination with the nucleic acid extraction solutions, GenoXtract® or GenoXtract® fleXT, the system provides a fully validated workflow for ease of implementation in your laboratory.

 

Please contact your local representative for availability in your country.

Not for sale in the USA.

Manufactured by Hain Lifescience GmbH – A Bruker Company